Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 12Small Cell Lung Carcinoma 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Mesothelioma 2Thymoma 1Somatostatinoma 1Recurrence 1Pheochromocytoma 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Insulinoma 1Hereditary Sensory and Autonomic Neuropathies 1Glucagonoma 1Gastrointestinal Neoplasms 1Gastrinoma 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Large Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 12Pemetrexed 11pembrolizumab 10Paclitaxel 6Cisplatin 6Erlotinib Hydrochloride 5Docetaxel 5Nivolumab 4Gefitinib 4spartalizumab 3osimertinib 3Gemcitabine 3EC145 3Crizotinib 3Afatinib 3technetium 99m etarfolatide 2pralsetinib 2fludarabine 2cemiplimab 2brigatinib 2alpha-2'-deoxythioguanosine 2aldesleukin 2Vinorelbine 2Radiotherapy 2Quality of Life 2MORAb-202 2Immunotherapy 2Drug Therapy 2Cyclophosphamide 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Everolimus × Thoracic × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡